Evidence map›Paper›PMID 42265698›Full record

ArticleJournal of biomedical science2026

Selective molecular and network architecture features underlie brain cortical atrophy in dementia with Lewy bodies.

Aline Delva, Stephen Joza, Christina Tremblay, Andrew Vo, Marie Filiatrault, Madeleine Carrier, John-Paul Taylor, John T O'Brien, Michael Firbank, Alan Thomas and 6 more

Abstract read
In one paragraph

Article in Journal of biomedical science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Aline DelvaThe Neuro (Montreal Neurological Institute-Hospital), McGill University, Montreal, Canada.ORCID http://orcid.org/0000-0001-8497-2314
Stephen JozaDivision of Neurology, Department of Medicine, University of Alberta, Edmonton, AB, Canada.
Christina TremblayCentre for Advanced Research in Sleep Medicine, Hôpital du Sacré-Coeur de Montréal, Quebec Integrated University Centre for Health and Social Services of Northern Island of Montreal, 5400 West Gouin Boulevard, Montreal, QC, H4J 1C5, Canada.
Andrew VoThe Neuro (Montreal Neurological Institute-Hospital), McGill University, Montreal, Canada.
Marie FiliatraultCentre for Advanced Research in Sleep Medicine, Hôpital du Sacré-Coeur de Montréal, Quebec Integrated University Centre for Health and Social Services of Northern Island of Montreal, 5400 West Gouin Boulevard, Montreal, QC, H4J 1C5, Canada.
Madeleine CarrierCentre for Advanced Research in Sleep Medicine, Hôpital du Sacré-Coeur de Montréal, Quebec Integrated University Centre for Health and Social Services of Northern Island of Montreal, 5400 West Gouin Boulevard, Montreal, QC, H4J 1C5, Canada.
John-Paul TaylorTranslational and Clinical Research Institute, Newcastle University, Newcastle, UK.
John T O'BrienDepartment of Psychiatry, University of Cambridge School of Clinical Medicine, Cambridge, UK.
Michael FirbankTranslational and Clinical Research Institute, Newcastle University, Newcastle, UK.
Alan ThomasTranslational and Clinical Research Institute, Newcastle University, Newcastle, UK.
Paul C DonaghyTranslational and Clinical Research Institute, Newcastle University, Newcastle, UK.
Richard CamicioliDivision of Neurology, Department of Medicine, University of Alberta, Edmonton, AB, Canada.
Howard ChertkowDepartment of Medicine (Neurology), University of Toronto, Toronto, ON, Canada.
Alain DagherThe Neuro (Montreal Neurological Institute-Hospital), McGill University, Montreal, Canada.
Ronald B PostumaThe Neuro (Montreal Neurological Institute-Hospital), McGill University, Montreal, Canada.
Shady RahayelCentre for Advanced Research in Sleep Medicine, Hôpital du Sacré-Coeur de Montréal, Quebec Integrated University Centre for Health and Social Services of Northern Island of Montreal, 5400 West Gouin Boulevard, Montreal, QC, H4J 1C5, Canada. shady.rahayel@umontreal.ca.ORCID http://orcid.org/0000-0001-5786-3278

Funding

Alzheimer Society 0000000082Michael J. Fox Foundation for Parkinson's Research MJFF-025745Parkinson Canada PPG-2023-0000000122
6 · The paper itself

Abstract

backgroundDementia with Lewy bodies shares clinical and pathological features with both Parkinson's disease and Alzheimer's disease, but the local biological factors that render specific cortical regions vulnerable to atrophy remain poorly defined. In particular, it is unclear whether cortical thinning in dementia with Lewy bodies reflects generic neurodegenerative mechanisms, processes shared with Parkinson's disease and Alzheimer's disease, or dementia with Lewy bodies-specific molecular and network susceptibilities.

methodsA total of 89 patients with dementia with Lewy bodies and 89 matched controls underwent T1-weighted brain MRI. Scans were processed to generate surface-based cortical thickness maps. Regional cortical thickness estimates, after slice-by-slice manual correction, were mapped to gene expression data from healthy postmortem human brains to identify transcriptomic signatures associated with decreased thickness in dementia with Lewy bodies. We assessed whether genes whose expression was increased with regional thinning converged onto established Parkinson's disease- and Alzheimer's disease-related pathways and identified genes uniquely implicated in dementia with Lewy bodies. Spatial annotation mapping was then used to test whether patterns of cortical thinning overlapped with in vivo neurotransmitter system distributions and whether the observed thickness pattern was constrained by large-scale structural connectivity, consistent with a network-based propagation process.

resultsCortical thinning predominated in regions that, in the healthy brain, show higher expression of genes involved in mitochondrial function and synaptic transmission. The transcriptomic profile associated with thinning significantly overlapped with genes belonging to Parkinson's disease and Alzheimer's disease pathways, supporting shared pathogenic mechanisms across Lewy body- and Alzheimer-type neurodegeneration. However, 90 genes associated with cortical thinning did not overlap with Parkinson's disease or Alzheimer's disease pathways and were enriched for GABAergic signalling. Spatial mapping analyses showed that regions with greatest thickness reductions colocalized with GABA

conclusionsMRI-derived cortical thickness changes in dementia with Lewy bodies reflect selective molecular and network vulnerabilities rather than a non-specific degenerative process. Mitochondrial and synaptic genes, together with a distinct GABAergic association and connectivity constraints, delineate mechanisms explaining why some cortical territories are more affected in dementia with Lewy bodies.

Indexed as

AtrophyCerebral CortexLewy Body DiseaseTranscriptomeAgedAged, 80 and overAlzheimer DiseaseFemaleHumansMagnetic Resonance ImagingMaleAlzheimer’s diseaseAtrophyConnectivityDementia with Lewy bodiesMRINeurodegenerationParkinson’s diseaseTranscriptomics

Identifiers

PMID42265698
PMCPMC13251274

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.